Lilly’s bamlanivimab plus etesevimab cut death, hospitalisations for early COVID-19 in Phase…
Results support use of bamlanivimab 700 mg and etesevimab 1400 mg, the dose authorised in the US and several other countries
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
BLAZE-1 trial
AbCellera gets EUA from US FDA for its antibody Bamlanivimab, along with Etesevimab for COVID-19
Lilly plans to manufacture more than 250,000 doses of the bamlanivimab and etesevimab therapy throughout Q1 2021, and up to a…